RU2014082C1 - Antitumoral agent - Google Patents

Antitumoral agent

Info

Publication number
RU2014082C1
RU2014082C1 SU3641428A RU2014082C1 RU 2014082 C1 RU2014082 C1 RU 2014082C1 SU 3641428 A SU3641428 A SU 3641428A RU 2014082 C1 RU2014082 C1 RU 2014082C1
Authority
RU
Russia
Prior art keywords
agent
preparation
antitumoral agent
systems
organs
Prior art date
Application number
Other languages
Russian (ru)
Inventor
Иван Анисимович Кулик
Original Assignee
Иван Анисимович Кулик
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иван Анисимович Кулик filed Critical Иван Анисимович Кулик
Priority to SU3641428 priority Critical patent/RU2014082C1/en
Application granted granted Critical
Publication of RU2014082C1 publication Critical patent/RU2014082C1/en

Links

Images

Abstract

FIELD: medicine. SUBSTANCE: preparation on the base of tannin is proposed as antitumor agent. Said preparation selectively affects tumoral process; organs and systems being unaffected. EFFECT: increases antitumor activity, decreases toxicity of agent.

Description

Изобретение относится к лекарственным средствам растительного происхождения и предназначено для лечения онкологического заболевания меланобластом. The invention relates to a herbal medicines and is intended for the treatment of oncological diseases melanoblasts.

Целью изобретения является поиск новых лекарственных средств, обладающих более высокой протипоопухолевой активностью и низкой токсичностью. The aim of the invention is to find new drugs having higher protipoopuholevoy activity and low toxicity.

П р и м е р 1. Смесь танина и йодида калия при соотношении 3:1 лиофилизируется, расфасовывается в стерильные флаконы объемом 20 мл и герметически закупариваются. EXAMPLE EXAMPLE 1. A mixture of tannin and potassium iodide at a ratio of 3: 1, lyophilized, packaged in sterile vials of 20 mL and hermetically zakuparivayutsya.

При лечении больных меланобластомами препарат растворяется 5%-ным раствором глюкозы объемом 20 мл и 20-миллилитровым шприцом вводится внутривенно 1 раз в сутки. When treating patients melanoblastoma drug dissolves a 5% glucose solution 20 ml and 20-ml syringe 1 is injected intravenously once a day. Курс лечения 15-30 суток внутривенных введений. The course of treatment 15-30 days of intravenous administration.

Эффективность предлагаемого средства в сравнении с ДТИК и полихимиотерапией проиллюстрирована данными таблицы. The effectiveness of the proposed agent in comparison with DTIK and polychemotherapy table illustrated data.

Как можно видеть из таблицы, эффективность флараксина составляет 90% в то время как ДТИК 15-20%, а полихимиотерапия 20-30%. As can be seen from the table, the efficiency is 90% FLARAXIN while DTIK 15-20% and 20-30% of the chemotherapy. Кроме того, химиотерапевтические противоопухолевые средства, все без исключения, обладают высокой степенью токсичности, что выражается в поражении органов, не только опухоленосителей, но и систем, не пораженных опухолью. Furthermore, chemotherapeutic antineoplastics, without exception, have a high degree of toxicity, which is expressed in affected organs, not only the tumor, but also systems that are not affected by the tumor. Высокая токсичность ограничивает назначение химиотерапии, в частности она противопоказана на терминальных стадиях заболевания опухолевым процессом. The high toxicity limits assignment chemotherapy in particular, it is counter to the terminal stages of the disease of cancer. Одна из постоянных патологий, которая ограничивает применение химиотерапии, поражение лейкоцитарного ростка крови, что вызывает стойкую лейкопению. One of the constants of pathologies, which restricts the use of chemotherapy, blood leukocyte defeat of the germ that causes persistent leukopenia.

Препарат флараксин относится к малотоксичным соединениям. FLARAXIN drug belongs to low-toxic compounds. Его применение для лечения меланобластом показало, что он действует избирательно на опухолевой процесс и не оказывает влияния на органы и системы. Its use for the treatment melanoblast showed that it acts selectively on tumor process and no effect on organs and systems. Это позволяет применять флараксин при различных стадиях заболевания, в том числе и терминальных. This allows you to apply FLARAXIN at different stages of the disease, including the terminal.

Claims (1)

  1. Применение таннина в качестве противоопухолевого средства для лечения меланомобластом. The use of tannin as an antitumor agent for treating melanomoblastom.
SU3641428 1983-07-08 1983-07-08 Antitumoral agent RU2014082C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SU3641428 RU2014082C1 (en) 1983-07-08 1983-07-08 Antitumoral agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU3641428 RU2014082C1 (en) 1983-07-08 1983-07-08 Antitumoral agent

Publications (1)

Publication Number Publication Date
RU2014082C1 true RU2014082C1 (en) 1994-06-15

Family

ID=21081461

Family Applications (1)

Application Number Title Priority Date Filing Date
SU3641428 RU2014082C1 (en) 1983-07-08 1983-07-08 Antitumoral agent

Country Status (1)

Country Link
RU (1) RU2014082C1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0896792A1 (en) * 1997-08-13 1999-02-17 Julphar Pharma GmbH Antiviral agent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0896792A1 (en) * 1997-08-13 1999-02-17 Julphar Pharma GmbH Antiviral agent
WO1999008536A1 (en) * 1997-08-13 1999-02-25 Julphar Pharma Gmbh Antiviral agent

Similar Documents

Publication Publication Date Title
Djerassi et al. Continuous infusion of methotrexate in children with acute leukemia
Klenner Observations on the dose and administration of ascorbic acid when employed beyond the range of a vitamin in human pathology
Earnest et al. Complications of intravenous phenytoin for acute treatment of seizures: recommendations for usage
RU2217145C2 (en) Heteroarylalkenyl derivatives of cyclopentaneheptan(en)oic acid
Vick et al. Neurological and physiological responses of the primate to anthrax toxin
Malpas et al. Rubidomycin in acute leukaemia in adults
BR9913157A (en) Process to treat or prevent infection caused by at least one virus of the Flaviviridae and diseases associated with such infection and infection caused by at least one virus of the genus Hepacivirus of Flaviviridade and diseases associated with such infections, the pharmaceutical composition to treat or prevent viral infections , it's composed
CN1187085C (en) Application of erythropoietin in producing medicine for treating cerebral ischemia
EA200000282A1 (en) The route of administration of the taxane to a patient in need of treatment a taxane, a method of treating a human taxane (variants)
BR9807892A (en) antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases.
BR0009647A (en) Docetaxel in combination with rhuMAb HER2 for treating cancers
BR9916732A (en) malÈnico acid derivatives, process for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
SE8402550L (en) N-substituted deridvat of moranoline
EP0619737A1 (en) Pharmaceutical composition for the treatment of wounds, scars and keloids
EA199901031A1 (en) benzimidazole derivatives
ES2007607A6 (en) A process for obtaining an insulin preparation for non-parenteral administration.
FR2279406A1 (en) New quinazoline derivatives and medicine containing them
IT1261849B (en) A medical device for the administration of active ingredients or in very low dosage drugs, particularly of homeopathic drugs.
ES2080549T3 (en) Based drugs polyhydroxymethylene derivatives, process for their preparation and use.
BR0013065A (en) A method and compound for treating a disease associated with recruitment and / or aberrant leukocyte activation
FI78236B (en) Foerfarande Foer framstaellning of a frystorkad doseringsenhet of cis-platinum (II) diamindiklorid.
KR0145739B1 (en) Effervescent tablet
Levitt et al. Bone marrow depression due to methicillin, a semisynthetic penicillin
Rosenberg Cisplatin: its history and possible mechanisms of action
EP0795561A4 (en) Novel anthracycline compound derivatives and medicinal preparations containing the same